Back to search results

RADIANT Study for Rare and Atypical Diabetes

The RADIANT (Rare and Atypical Diabetes Network) study is looking for people with unusual forms of diabetes to better understand these conditions. This observational study aims to identify and enroll individuals and families with previously unknown types of diabetes. Researchers will use Whole Genome Sequencing (WGS), which looks at all your genes, and other detailed tests to find the genetic causes and how these forms of diabetes affect the body. The goal is to define new forms of diabetes and the unique ways they develop. There are no specific interventions or drugs being tested in this study. The study is currently unclear on its recruitment status and plans to enroll 2000 participants.

Study design
This is an observational study, meaning researchers will collect information about your health without giving you any specific treatments. It aims to enroll 2000 participants.
What's involved
You would complete questionnaires and provide blood samples for genetic testing and other analyses. Some participants may undergo more detailed testing in later stages.
Compensation
Not stated in the trial record.
Follow-up
Your health will be followed through study completion, which is an average of 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05544266

Rare and Atypical Diabetes Network

Recruiting
Not specifiedAll AgesObservational
University of South Florida
~2,000 participants
Updated 2025-08-14 on ClinicalTrials.gov

At a glance

Recruiting sites
13 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phenotypic and genotypic characterization of previously unknown forms of diabetes using Whole Genome Sequencing (WGS), and deeper phenotyping methods
Measured over Through study completion, an average of 3 years.

Conditions

Diabetes Mellitus
Diabetes Mellitus Progression
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Disease
Endocrine; Complications
Endocrine System Diseases

Explore related trials

Atypical DiabetesDiabetes Mellitus

Where it's being run

13 sites across 12 states
New York2
Colorado1
Illinois1
Indiana1
Maryland1
Massachusetts1
Michigan1
Missouri1

Study leadership

  • Jeffrey Krischer, PhD · STUDY_CHAIR · University of South Florida

Who to contact

Jeffrey Krischer, PhD
[email protected]
813-396-9501
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese
Mendelian pattern, especially with early onset (\<18 years old)
Syndromic (multiple systems involved)
Lipodystrophic
Extremes of BMI
"Mitochondrial" characteristics (e.g., myopathy, hearing deficits)
Non-progressive
Rapidly progressive ("fulminant")
Low insulin requirements (\<0.5 u/kg/day)
Cyclical hyperglycemia with periods of remission
Lean persons with polycystic ovarian syndrome (PCOS)
History of gestational diabetes (GDM) when lean
Lean insulin-resistant persons
If islet autoantibodies and beta-cell function parameters have been measured (where "A" = islet cell autoantibodies, "B" = beta-cell function):

Exclusion

Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes
Refusal of consent for genetic testing
Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)
Women who are currently pregnant

What this trial measures

  • Phenotypic and genotypic characterization of previously unknown forms of diabetes using Whole Genome Sequencing (WGS), and deeper phenotyping methodsThrough study completion, an average of 3 years.

    Deeper phenotyping methods include both clinical and laboratory assessments. Clinical data includes anthropometric and biometric data, medical histories, and standard questionnaires (ASA24, PROMIS, environmental exposures depression and anxiety). Laboratory data includes WGS, transcriptomics, metabolomics, mitochondrial sequencing, Oral Glucose Tolerance Test (OGTT), and Islet autoantibodies. Clustering methods will be used to define cohorts of similar diabetes genotypes and phenotypes based on this data.